Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration

AbCellera Biologics Inc. (NASDAQ:ABCL) is among the Best Pharmaceutical Stocks.

On June 17, 2026,  AbCellera Biologics Inc. (NASDAQ:ABCL) and Jazz Pharmaceuticals entered a preclinical research collaboration, option, and license agreement. The deal is to discover and develop next-generation T-cell multispecific antibodies targeting gastrointestinal cancers and other solid tumors.

The companies said the partnership includes $56 million in upfront payments to AbCellera Biologics Inc. (NASDAQ:ABCL) and up to $792 million in potential option fees and milestone payments for programs Jazz elects to advance. Jazz holds the exclusive option to develop and market resulting therapeutic antibodies.

AbCellera founder and CEO Carl Hansen, Ph.D., said the deal leverages its T-cell engager platform. Hansen described it as a fully integrated system covering discovery to clinical manufacturing, designed for developing multispecific antibodies for difficult-to-treat cancers.

Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment

Jazz Pharmaceuticals chief scientific officer in oncology, Josh Allen, Ph.D., said the collaboration is in line with Jazz’s rare disease strategy, growing its oncology focus into GI cancers.

AbCellera Biologics Inc. (NASDAQ:ABCL) works in the making of therapeutic antibodies. It gives an antibody discovery platform that searches, decodes, and analyzes natural immune systems to identify antibodies that can be produced to prevent and treat disease.

While we acknowledge the risk and potential of ABCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABCL and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1